BofA warns Fed risks policy mistake with early rate cuts
SANTA MONICA, Calif. - GoodRx Holdings, Inc. (NASDAQ:GDRX) saw its shares soar 10.8% after the medication savings platform reported first quarter revenue that beat analyst expectations and maintained its full-year guidance.
The company posted Q1 revenue of $203.0 million, edging past the consensus estimate of $202.59 million. Adjusted earnings per share came in at $0.09, in line with analyst projections.
GoodRx’s prescription transactions revenue, its largest segment, grew 2% YoY to $148.9 million. The company attributed this to improved unit economics, partially offset by a 4% decrease in Monthly Active Consumers.
"I can confidently say that we are in a very strong position to deliver meaningful value across the pharmacy ecosystem," said CEO Wendy Barnes.
For the full year 2025, GoodRx maintained its revenue guidance of $810-$840 million, in line with the $823.3 million analyst consensus. The company slightly raised its adjusted EBITDA outlook to $273-$287 million.
CFO Chris McGinnis noted the company has "greater conviction and visibility at the lower half of our range with achievement of strategic initiatives providing opportunities to deliver in the upper half of our range."
GoodRx exited Q1 with over 7 million consumers of prescription-related offerings. The strong quarterly results and maintained outlook drove the stock’s double-digit gain in after-hours trading.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.